{"name":"Sun Pharmaceutical Industries Limited","slug":"sun-pharmaceutical-industries-limited","ticker":"","exchange":"","domain":"sunindustrieslimited.com","description":"","hq":"Mumbai","founded":0,"employees":"","ceo":"Dilip Shanghvi","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":6,"colorKey":"oncology","drugs":[{"name":"GL0034 Dose Level 2","genericName":"GL0034 Dose Level 2","slug":"gl0034-dose-level-2","indication":"Other","status":"phase_2"},{"name":"GL0034 Dose Level 4","genericName":"GL0034 Dose Level 4","slug":"gl0034-dose-level-4","indication":"Other","status":"phase_2"},{"name":"Bromday™","genericName":"Bromday™","slug":"bromday","indication":"Other","status":"marketed"},{"name":"GL0034 Dose Level 6","genericName":"GL0034 Dose Level 6","slug":"gl0034-dose-level-6","indication":"Other","status":"phase_2"},{"name":"MM-II dose I","genericName":"MM-II dose I","slug":"mm-ii-dose-i","indication":"Other","status":"phase_2"},{"name":"matching placebo injections","genericName":"matching placebo injections","slug":"matching-placebo-injections","indication":"Comparing the efficacy of a new drug to a placebo","status":"phase_3"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"immunology","drugs":[{"name":"TILD","genericName":"TILD","slug":"tild","indication":"Plaque psoriasis","status":"marketed"},{"name":"Halobetasol Topical Lotion","genericName":"Halobetasol Topical Lotion","slug":"halobetasol-topical-lotion","indication":"Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses","status":"marketed"},{"name":"Injections of tildrakizumab","genericName":"Injections of tildrakizumab","slug":"injections-of-tildrakizumab","indication":"Moderate to severe plaque psoriasis","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"infectious","drugs":[{"name":"ISV-303","genericName":"ISV-303","slug":"isv-303","indication":"Cancer (specific indication under clinical evaluation in Phase 3)","status":"phase_3"},{"name":"ISV-305","genericName":"ISV-305","slug":"isv-305","indication":"Oncology indication (specific indication not publicly confirmed)","status":"phase_3"}]},{"name":"Neuroscience","slug":"neuroscience","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"rare","drugs":[{"name":"PART 1: Double-blind Placebo-controlled","genericName":"PART 1: Double-blind Placebo-controlled","slug":"part-1-double-blind-placebo-controlled","indication":"Major depressive disorder","status":"phase_3"},{"name":"SAPHRIS","genericName":"SAPHRIS","slug":"saphris","indication":"Schizophrenia","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Zero-dose","genericName":"Zero-dose","slug":"zero-dose","indication":"COVID-19 prevention","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"neuroscience","drugs":[{"name":"Brinzolamide ophthalmic suspension","genericName":"Brinzolamide ophthalmic suspension","slug":"brinzolamide-ophthalmic-suspension","indication":"Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"respiratory","drugs":[{"name":"OTX-101 0.09%","genericName":"OTX-101 0.09%","slug":"otx-101-0-09","indication":"Treatment of dry eye disease","status":"phase_3"}]},{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"metabolic","drugs":[{"name":"SPIL1033","genericName":"SPIL1033","slug":"spil1033","indication":"Type 2 diabetes","status":"phase_3"}]}],"pipeline":[{"name":"GL0034 Dose Level 2","genericName":"GL0034 Dose Level 2","slug":"gl0034-dose-level-2","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GL0034 Dose Level 4","genericName":"GL0034 Dose Level 4","slug":"gl0034-dose-level-4","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"TILD","genericName":"TILD","slug":"tild","phase":"marketed","mechanism":"Tild is a small molecule that works by interacting with a specific target in the body.","indications":["Plaque psoriasis"],"catalyst":""},{"name":"Zero-dose","genericName":"Zero-dose","slug":"zero-dose","phase":"phase_3","mechanism":"Zero-dose is a vaccine candidate that uses a novel approach to stimulate an immune response without the need for a traditional vaccine dose.","indications":["COVID-19 prevention"],"catalyst":""},{"name":"Brinzolamide ophthalmic suspension","genericName":"Brinzolamide ophthalmic suspension","slug":"brinzolamide-ophthalmic-suspension","phase":"phase_3","mechanism":"Brinzolamide is a carbonic anhydrase inhibitor that reduces aqueous humor production in the eye, thereby lowering intraocular pressure.","indications":["Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma"],"catalyst":""},{"name":"Bromday™","genericName":"Bromday™","slug":"bromday","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"GL0034 Dose Level 6","genericName":"GL0034 Dose Level 6","slug":"gl0034-dose-level-6","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Halobetasol Topical Lotion","genericName":"Halobetasol Topical Lotion","slug":"halobetasol-topical-lotion","phase":"marketed","mechanism":"Halobetasol is a potent topical corticosteroid that suppresses inflammatory and immune responses in the skin by binding to glucocorticoid receptors.","indications":["Inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses","Severe dermatitis, psoriasis, and lichen planus (topical)"],"catalyst":""},{"name":"ISV-303","genericName":"ISV-303","slug":"isv-303","phase":"phase_3","mechanism":"ISV-303 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.","indications":["Cancer (specific indication under clinical evaluation in Phase 3)"],"catalyst":""},{"name":"ISV-305","genericName":"ISV-305","slug":"isv-305","phase":"phase_3","mechanism":"ISV-305 is an investigational immunotherapy designed to enhance anti-tumor immune responses through modulation of the immune checkpoint pathway.","indications":["Oncology indication (specific indication not publicly confirmed)"],"catalyst":""},{"name":"Injections of tildrakizumab","genericName":"Injections of tildrakizumab","slug":"injections-of-tildrakizumab","phase":"marketed","mechanism":"Tildrakizumab is a monoclonal antibody that selectively blocks interleukin-23 (IL-23) to reduce inflammatory immune responses in the skin.","indications":["Moderate to severe plaque psoriasis","Psoriatic arthritis"],"catalyst":""},{"name":"MM-II dose I","genericName":"MM-II dose I","slug":"mm-ii-dose-i","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"OTX-101 0.09%","genericName":"OTX-101 0.09%","slug":"otx-101-0-09","phase":"phase_3","mechanism":"OTX-101 is a topical ophthalmic solution used to treat dry eye disease.","indications":["Treatment of dry eye disease"],"catalyst":""},{"name":"PART 1: Double-blind Placebo-controlled","genericName":"PART 1: Double-blind Placebo-controlled","slug":"part-1-double-blind-placebo-controlled","phase":"phase_3","mechanism":"This drug is a selective serotonin reuptake inhibitor.","indications":["Major depressive disorder","Generalized anxiety disorder"],"catalyst":""},{"name":"SAPHRIS","genericName":"SAPHRIS","slug":"saphris","phase":"marketed","mechanism":"SAPHRIS (asenapine) is an atypical antipsychotic that blocks dopamine and serotonin receptors in the brain to reduce psychotic symptoms and mood disturbances.","indications":["Schizophrenia","Bipolar I disorder (acute manic or mixed episodes)"],"catalyst":""},{"name":"SPIL1033","genericName":"SPIL1033","slug":"spil1033","phase":"phase_3","mechanism":"SPIL1033 is a small molecule drug that targets the SGLT2 receptor.","indications":["Type 2 diabetes"],"catalyst":""},{"name":"matching placebo injections","genericName":"matching placebo injections","slug":"matching-placebo-injections","phase":"phase_3","mechanism":"Matching placebo injections are used to compare the efficacy of a new drug to a placebo.","indications":["Comparing the efficacy of a new drug to a placebo"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxPaC02RGtlTU9NQlRLMjFjTGwwdXJNMzlMN1pMMGFBV2VZSXp6c1hUX2dyaGZrMlVtcU1YWlAyM3VJaFlubnMzTU1MOTdpTTRJRzNVajJaRi01MmZ4UmNGZlFQMGJyVmpWSk1IS0dSZE53TFdUa0dYZkJfY3FvUHVDSlliRk5qSHg0VWhnRzJ4UnNEc2RpZWg1NEVzMFY3LWRCMmcwWnRUMXJCUmdCeEExWkxLaVlBSHVSMHppRnFNdzJNQQ?oc=5","date":"2026-04-08","type":"pipeline","source":"TipRanks","summary":"Sun Pharma Publishes Postal Ballot and E-Voting Notices for Shareholders - TipRanks","headline":"Sun Pharma Publishes Postal Ballot and E-Voting Notices for Shareholders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxQRU1pdVJ6ZVZkVnUzMHg5eGt6RXlYQ1NqNFN4dVhXbzN3bWR3U2pMbEFveUZIWGRVdjU1dVNReGsxRnRrUlZWbm5xRDJ3MDZSZDNtSnF1bVVDNlZmc09QUmZKbUR3NFR0SUJMcXp5aEp6clVTQURJNW82TUpMN1ZQbnU4eElXbG9SRU1fN2NOMldBQkNYX2lNV3N5SG9TOGl4SVhuNTBUcHJRMjVSNFdPSjcwZGh1X2ZvNlA3UWN1WFVfV2V1Yi1JZEx6ZnliaWcxd0E?oc=5","date":"2026-04-08","type":"pipeline","source":"scanx.trade","summary":"Sun Pharma Publishes Postal Ballot Newspaper Ads for Director Appointment - scanx.trade","headline":"Sun Pharma Publishes Postal Ballot Newspaper Ads for Director Appointment","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"earnings","source":"NDTV Profit","summary":"Sun Pharma In Focus: US Tariffs A Bitter Pill For Sector, But Brokerages See Manageable Impact - NDTV Profit","headline":"Sun Pharma In Focus: US Tariffs A Bitter Pill For Sector, But Brokerages See Manageable Impact","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-04-06","type":"pipeline","source":"Business Standard","summary":"Sun Pharmaceutical Industries Ltd eases for fifth straight session - Business Standard","headline":"Sun Pharmaceutical Industries Ltd eases for fifth straight session","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxQeVNrVnNQQnM4aURxREdSa29xQXY3T0ZPNl9mSTN2VHhPbWExbFlHRFZiTXJEYmVzOVlfMERUQlJtTTh4bGVhZnlOMnFqd1VtVUhMYUctd0U0VUNlcHp2OEpOQzh5V0YxejlKb2ZXSDNhcEk3ZERQRFNweVo1RHBDanp2dVZXdDhkcG1XUUpxd284MU9UTTFMdUxwQm5lLTBHQzV1c2NaMU9LY3Y0?oc=5","date":"2026-04-06","type":"deal","source":"Markets Mojo","summary":"Sun Pharmaceutical Industries Ltd is Rated Buy - Markets Mojo","headline":"Sun Pharmaceutical Industries Ltd is Rated Buy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxNSEZwSUNsR0x4a1ZkNmRNVklJdVJXTlpXbW1NTkFmSHpwZzZIb2h0OUplUXFFMjNzZ0I1ek9jZHBrOGY5SnJ5cDlXTGZYUTFOVk9HUkRUQWh0RVZWUTlweC1LZW9fVWZ0T3pycEJjTm5TZ3diNXFxQjlhZEZHY3h1Slo4c1VLSDRQRDBzbGVSTW5fTy1zVmluY1g0WWdsSzJ4QjdMTk9pY2psRi1CMV90RlhxVUszekNUUEFOc2tfQURYMUktb0JReC1YUlRYdlFMckc3VktmQUdZdw?oc=5","date":"2026-04-06","type":"earnings","source":"scanx.trade","summary":"Sun Pharmaceutical Industries Files Q4FY26 Depository Compliance Certificate - scanx.trade","headline":"Sun Pharmaceutical Industries Files Q4FY26 Depository Compliance Certificate","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQdjZvSV9rd0tISlJ0U0l5MkdaYURuRmUtTV9NQ0hEeDFJZWJfRl9raGVLcTlsOEgzSlFDdVNzS012S3pSbnNNZE85Z25KT2JvelVjVm5nMXpxbzZ2NEVvZmxZRXh6YU5qNFNjc2xpUVAxbTBoOUhPQkhIX0ZPRVJfMWdmOTAwNTdpeThaSmpNSEVYek9vVGVCcEhzOVhSZ2VQempFNVZ5Ri1nUEJ5cUtzXzBBbUNZRWJVbkRyT2dZcVRCa2tMSHU5RjVHU3c4TFo0MnljaFAtZE5GalBha2R0QTdVN01BWm92WmlnV1I3eGtrdw?oc=5","date":"2026-03-27","type":"pipeline","source":"PR Newswire","summary":"Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting - PR Newswire","headline":"Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi7AFBVV95cUxPZURLdzMtT3JIMFFTRzhsd21pVWtGZ0dTX0NlMkdLSmJTN0tCR1JzdlpvUFNTUGE2MThoM0tJVUlsZjlHeTU2RkljMnVVZ3RZbzdyal9qUW0zMWJSQWZoOXMzZmFPOGVqTmMyLWRDSkloMzlycWhiQjYwOE5td0F1czh1a1UzS1V3aGtTS3RtUFpPSV9ndnNybDhlel9RWjVHc0ZlTVBKZXlWYXNFWmV1QmtMNWRMQ2c1aG9EMHBvYkt2SXNWQlhra1ZmOGtBcGN5WGQ3VXMwVHp4XzRoUGlyR0hjRXp0SkprR0dOMg?oc=5","date":"2026-02-27","type":"trial","source":"PR Newswire","summary":"Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami - PR Newswire","headline":"Sun Pharma Showcases Data Across its Dermatology & Immunology Portfolio at 2026 Winter Clinical Miami","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxQeHlCV0dELWJaQ3JFQi1HeHlvcFpQaDhxN1ROdDBQMlpXR2kydk5FQmNoVm9ZeTZCVkZBWVNvZlZzRnBUWmlLLXMzLXdRS2JkYUhQem1HMHZySzZ2bDlvU0pOLWZwSWlXbHZaLTVreDlkQmVXQ1FSeWhreTFRNUZONDhmd2g3RWppQkdWT3R4bDVZNkhZcUtleFF6NWd2S2RXN0owWlYzSkwySFE5NExDLWxpU014eHA1TTgyNFRtUThoakx1WEY0?oc=5","date":"2026-01-26","type":"pipeline","source":"reuters.com","summary":"China halts sale of Sun Pharma drug used to treat dementia - reuters.com","headline":"China halts sale of Sun Pharma drug used to treat dementia","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOaFFMZ0YwQ0cwZnZUd2ZJaE5lRzZIS09ZZDFYdGstYXRSNXlmeEJzVXpCYTJ5M0laSHc3RU05dHBDMlJBRWcwWUM3UmtnWXdybFdxYUJLbXRSY1RNU2NqVWNMdTZ1elYxLS1CMUJ2Zm1GMXdUMDVaQW1ST0p3M0V0cElWbDNzelRDZktJY0FobWZrS1VKdlZycFNQYm5YcFFNY0hYSThPdnc3Qy1VWXBNOURKVEJ3Zw?oc=5","date":"2026-01-21","type":"pipeline","source":"bloomberg.com","summary":"India’s Biggest Pharma Firm Said to Mull Bid for New York-Listed Organon - bloomberg.com","headline":"India’s Biggest Pharma Firm Said to Mull Bid for New York-Listed Organon","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQUWw5dTd1SUM0RVdZby1sMnhfRTd1MUtiNlplc3oyQ254WVg4VVlrZVRubmxKY3pqUzUwNlRCWFpINjRuZGNfeXlwVDJyTUtLRlBod20yT1VoaFRQMVVWRlVjdllKNmRqeThTNjVNanRSd1QyRWVOYjF5Z3JqYmRPaGEybjlUbzNxbnQyelRHOWlDaGRZQ2dZM3llMmo5NjRtNkc4eUNZOXF5QjhhdUY0T195REFyMUhEVVZNag?oc=5","date":"2025-11-05","type":"earnings","source":"reuters.com","summary":"India's Sun Pharma beats Q2 profit estimates, targets growth through drug launches - reuters.com","headline":"India's Sun Pharma beats Q2 profit estimates, targets growth through drug launches","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNVzJpOUxrMWYtY05uWEI3akdXVllDRkNnUlNUNl9DR2VrbjFxTTZyUF9YSmtvSDB0eFhCRVFIeDJyMk9vcDFUSzlfYkRzeXJ3VHJudjM5bVBVVXR5ejNwZzJOc01ib0VvWkN3cTJKOTdLb0VXSUdhdDZ2RXo0OWFWSDZrVDRqRXU0QklSSkVoaGRsZjdCeDF5SDlPU2JjcERVajctZkluaGducUIxMHBF?oc=5","date":"2025-10-23","type":"pipeline","source":"ROI-NJ","summary":"Allen named VP, corporate affairs for North America at Sun Pharma - ROI-NJ","headline":"Allen named VP, corporate affairs for North America at Sun Pharma - ROI","sentiment":"neutral"}],"patents":[],"drugCount":17,"phaseCounts":{"phase_2":4,"marketed":5,"phase_3":8},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}